Travere Therapeutics

TVTX · NASDAQ

$52.30+$1.81 (+3.58%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $50.49

About TVTX

Travere Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 497 full-time employees. The company went IPO on 2003-07-23. The firm is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Employees: 497
Headquarters: San Diego, California
Listed: Jul 23, 2003
Sector: Health Care
Industry: Biotechnology
Website: travere.com

Leadership

Travere Therapeutics executives
Name	Title	Since	Age
Gary Lyons	—	—	73
Eric Dube	—	2019	52
Christopher Cline	—	—	41
Elizabeth Reed	—	—	54
Peter Heerma	—	—	54
Jula Inrig	—	—	50
William Rote	—	—	62
Roy Baynes	—	—	70
Suzanne Bruhn	—	—	61
Timothy Coughlin	—	—	58
Jeffrey Meckler	—	—	58
John Orwin	—	—	63
Sandra Poole	—	—	61
Ron Squarer	—	—	58
Ruth Williams-Brinkley	—	—	73

Revenue by product and region

Fiscal year ended Dec 31, 2025: $490.73M total revenue

By product

Net product sales$410.46M83.6%
License and collaboration revenue$80.27M16.4%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Travere Therapeutics suppliers and customers
Company	Relationship	Country	Correlation
Thermo Fisher Scientific TMO	Supplier and customer	US	0.77
Vifor Pharma VIFN.SW	Supplier and customer	CH	0.35
Ligand Pharmaceuticals LGND	Supplier and customer	US	0.28
Omnicom OMC	Supplier	US	-0.10
Albireo Pharma ALBO	Supplier and customer	US	-0.40
Eversana Life Science Services LLC	Customer	US	—
Mission Pharmacal Co.	Supplier and customer	US	—
Nexgen Pharma (TM), Inc.	Supplier and customer	US	—
Alagille Syndrome Alliance	Supplier and customer	US	—
United States	Supplier and customer	US	—

Similar companies

Companies in the same industry as Travere Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.